Article Versions Notes

Convertino I, Lorenzoni V, Gini R, Turchetti G, Fini E, Giometto S, Bartolini C, Paoletti O, Ferraro S, Cappello E, et al. Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals. 2023; 16(3):465. https://doi.org/10.3390/ph16030465

Convertino, Irma, Valentina Lorenzoni, Rosa Gini, Giuseppe Turchetti, Elisabetta Fini, Sabrina Giometto, Claudia Bartolini, Olga Paoletti, Sara Ferraro, Emiliano Cappello, and et al. 2023. "Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis" Pharmaceuticals 16, no. 3: 465. https://doi.org/10.3390/ph16030465

Convertino, I., Lorenzoni, V., Gini, R., Turchetti, G., Fini, E., Giometto, S., Bartolini, C., Paoletti, O., Ferraro, S., Cappello, E., Valdiserra, G., Bonaso, M., Blandizzi, C., Tuccori, M., & Lucenteforte, E. (2023). Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals, 16(3), 465. https://doi.org/10.3390/ph16030465